Medicines Co. (MDCO) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
The Medicines Company Reports Second-Quarter and First-Half 2015 Financial Results
July 29, 2015 7:00 AM EDTCommercial resources focused on new product launches R&D investment in potential blockbusters continues Company contracts with Sandoz for launch of authorized generic bivalirudin (Angiomax) Company exploring strategic-partnering options to accelerate business development and unlock value
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the second quarter and first half of 2015.
Clive Meanwell, the companys Chairman and Chief Executive... More
